abrdn plc — 2024 Investments

3 investments dated 2024 · listed companies and verified rows first · show all

Alpha-9 Oncologya9oncology.com inOct 2024

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)

Co-investorsAndreessen Horowitz Ascenta Capital Delos Capital Frazier Life Sciences General Catalyst Lightspeed Venture Partners +9 more

Nuvig Therapeuticsnuvigtx.comDec 2024

Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function.

BiotechLongevity

Co-investorsSanofi Ventures Alexandria B Capital Digitalis Ventures Global BioAccess Fund Leaps by Bayer +4 more

Qlaris Bioqlaris.bio inMay 2024 · $24M

Qlaris Bio is a clinical-stage biotechnology company developing therapies for ophthalmology conditions.

BiotechMedical DevicesDedham, US

Thurein Htoo(Executive Officer, Director)inFred Guerard(President & Chief Executive Officer)inBarbara Wirostko(Executive Officer)

BoardWende Hutton(Director)inRonald M. Hunt(Director)Andrew Danielson(Director)

Co-investorsCanaan Partners Correlation Ventures Mayo Clinic Ventures New Leaf Venture Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.